Alaunos Therapeutics Inc (TCRT)

Form 4 - Statement of changes in beneficial ownership of securities

Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies

ALN1003 demonstrated consistent, favorable effects across key drivers of metabolic disease, including...

Form 8-K - Current report

Form 8-K - Current report

Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models

FORT LAUDERDALE, Fla., May 18, 2026 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Nasdaq: TCRT) today...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Valion Bio Appoints Melinda Lackey as General Counsel

Valion Bio Appoints Melinda Lackey as General Counsel PR Newswire SAN ANTONIO, May 4, 2026 Seasoned...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]

Form 8-K - Current report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Alaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic Disorders

The lead drug candidate, ALN1003, showed dose-related body weight loss and favorable body composition changes...